2016
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro
Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecologic Oncology 2016, 144: 146-152. PMID: 27894751, PMCID: PMC5183545, DOI: 10.1016/j.ygyno.2016.11.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsCarboplatinCarcinomaCD4 Lymphocyte CountCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell SurvivalDisease-Free SurvivalDNA Polymerase IIDrug Resistance, NeoplasmEndometrial NeoplasmsFemaleHumansMicrosatellite InstabilityMiddle AgedMutationPoly-ADP-Ribose Binding ProteinsTumor Cells, CulturedConceptsBetter prognosisTumor cell linesInfiltration of CD4Number of CD4Platinum-based chemotherapyT lymphocyte infiltrationPD-1 receptorCell linesLow metastatic capabilityPOLE-mutated tumorsWild-type ECsEC cell linesLymphocyte infiltrationFavorable prognosisPD-1EC patientsType tumorsEnhanced immunogenicityT lymphocytesMolecular subtypesTumors correlatesChemotherapyMetastatic capabilityPrognosisTumors
2007
Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease
Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, Schwartz PE. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecologic Oncology 2007, 105: 211-217. PMID: 17239941, DOI: 10.1016/j.ygyno.2006.11.025.Peer-Reviewed Original ResearchConceptsProgression-free survivalExtra-abdominal diseasePeri-operative morbidityStage IV diseaseOverall survivalPDS groupNAC patientsAggressive surgeryNeoadjuvant chemotherapyNAC groupOvarian cancerAdjuvant platinum-based chemotherapyAdvanced epithelial ovarian cancerImproved progression-free survivalIntra-operative blood lossFurther aggressive surgeryUnits of transfusionAdvanced ovarian cancerShorter hospital stayPlatinum-based chemotherapyTreatment of choiceEpithelial ovarian cancerAdvanced EOCOptimal cytoreductionCytoreductive surgery
2005
Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy
Kelly MG, O'Malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, Azodi M, Schwartz PE. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecologic Oncology 2005, 98: 353-359. PMID: 16005947, DOI: 10.1016/j.ygyno.2005.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiopsy, NeedleChemotherapy, AdjuvantCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousDilatation and CurettageDisease-Free SurvivalFemaleHumansHysterectomyNeoplasm StagingOrganoplatinum CompoundsRetrospective StudiesUterine NeoplasmsConceptsUterine papillary serous carcinomaPlatinum-based chemotherapyResidual uterine diseaseStage IA patientsVaginal cuff radiationAdjuvant platinum-based chemotherapySurgical stage IPapillary serous carcinomaIA patientsUterine diseaseStage IHysterectomy specimenOverall survivalSerous carcinomaConcomitant platinum-based chemotherapyImproved disease-free survivalComplete surgical stagingStage IB patientsStage IC patientsDisease-free survivalHigh recurrence rateVaginal radiationAdjuvant therapyStage IASurgical staging